Tirzepatide: Benefits & Research
Part of the Tirzepatide Complete Guide
Partner
Shop Peptides at BioLongevity LabsResearch Peptides
BioLongevity Labs15% Off
We may earn a commission if you purchase through this link, at no extra cost to you.
Weight Loss
SURMOUNT-1 trial results (72 weeks, non-diabetic adults with obesity):
| Dose | Mean Weight Loss | ≥20% Loss |
|---|---|---|
| 5 mg | -15.0% | 32% |
| 10 mg | -19.5% | 46% |
| 15 mg | -20.9% | 57% |
SURMOUNT-5 head-to-head: tirzepatide 15mg achieved -20.2% vs -13.7% for semaglutide 2.4mg — statistically superior.
Diabetes Management
SURPASS program results in type 2 diabetes:
- HbA1c reductions of -2.0 to -2.6%
- Up to 34% achieved HbA1c <5.7% (normal range)
- Superior to semaglutide 1mg in head-to-head (SURPASS-2)
- Superior to insulin degludec and insulin glargine
Cardiovascular Benefits
Improvements in blood pressure, triglycerides, and inflammatory markers observed across trial programs. Dedicated cardiovascular outcomes trials are ongoing. For the next-generation triple agonist, see retatrutide. For broader context, see peptides for weight loss.